Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 59 out of 100. Getting a diagnosis

Topic: Risk, prevention and care in population studies

Since its opening in 2000, patient care and research go hand in hand at the Alzheimer center of the VU University Medical Center, both organized in such a way that they mutually strengthen each other. Our mission is to give patients a voice by lifting the stigma on dementia, to find new diagnostic and treatment strategies, and, ultimately, to cure diseases that cause dementia. Our healthcare pathway is uniquely designed to accommodate all necessary investigations for the diagnostic work-up of dementia in one day (one-stop shop). A second unique feature is that research has been fully integrated in the healthcare pathway. The resulting Amsterdam Dementia Cohort now includes over 4000 patients, and for the majority of these, we have MRI, EEG, blood (serum, plasma), DNA, and CSF available. The Amsterdam Dementia Cohort forms the basis of much of our research, which focuses on four major research lines: 1) variability in manifestation, 2) early diagnosis, 3) vascular factors, and 4) interventions. By answering research questions closely related to clinical practice, the results of our research can be looped back to improve clinical work-up for our patients.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

van der Flier, W. M., Pijnenburg, Y. A., Prins, N., Lemstra, A. W., Bouwman, F. H., Teunissen, C. E., et al. (2014). Optimizing patient care and research: the Amsterdam Dementia Cohort. Journal of Alzheimer's disease : JAD. https://doi.org/10.3233/jad-132306

Vancouver

van der Flier WM, Pijnenburg YA, Prins N, Lemstra AW, Bouwman FH, Teunissen CE, et al. Optimizing patient care and research: the Amsterdam Dementia Cohort. Journal of Alzheimer's disease : JAD. 2014. doi:10.3233/jad-132306. PMID: 24614907.

BibTeX

@article{vanderflier2014-24614907,
  author  = {van der Flier, W. M. and Pijnenburg, Y. A. and Prins, N. and Lemstra, A. W. and Bouwman, F. H. and Teunissen, C. E. and van Berckel, B. N. and Stam, C. J. and others},
  title   = {{Optimizing patient care and research: the Amsterdam Dementia Cohort}},
  journal = {Journal of Alzheimer's disease : JAD},
  year    = {2014},
  doi     = {10.3233/jad-132306},
  pmid    = {24614907},
  url     = {https://doi.org/10.3233/jad-132306}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This paper describes the Amsterdam Dementia Cohort, which combines patient care and research and includes over 4000 patients with data such as MRI, EEG, blood, DNA, and CSF. It is a research infrastructure and does not itself report a treatment, cure, or prevention for Alzheimer's disease.

Study details

How this study scored 59/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 0 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 1 of 5; Sample size 3 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomised / blinded 0 of 2; Times cited 6 of 7; Citations per year 4 of 5; Impact for its field and year 5 of 6; Cited by studies here 4 of 6; Still being cited 3 of 4; Senior author's track record 4 of 4; Institution's track record 1 of 3; Multi-centre collaboration 1 of 3; Indexed in PubMed 2 of 2; Free to read 0 of 2. Total 59 of 100.59 of 100 points earned41 not earned

Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomised / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Journal of Alzheimer's disease : JAD)
Journal's citation record 2 / 4 Journal of Alzheimer s Disease: journal h-index 218 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 1 / 5 2014 — within 20 year(s) of the newest study here
Sample size 3 / 4 4,000 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomised / blinded 0 / 2 No randomisation or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 401 times (OpenAlex, 2026-10-10)
Citations per year 4 / 5 28.6 citations a year over 14 year(s) since 2014
Impact for its field and year 5 / 6 Cited 23.7× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 42 other studies in this library
Still being cited 3 / 4 Cited 77 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Philip Scheltens: h-index 181 (OpenAlex, whole career)
Institution's track record 1 / 3 Amsterdam UMC Location Vrije Universiteit Amsterdam: institution h-index 938 (OpenAlex)
Multi-centre collaboration 1 / 3 OpenAlex lists 2 institution(s) in 1 country
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 24614907)
Free to read 0 / 2 Behind a paywall — scores zero
Total 59 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 33.

Later studies that cite this one

42 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Getting a diagnosis

Also tagged “prevalence”

1,223 studies in the library carry the topic tag “prevalence”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 1,223 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Getting a diagnosis

See all studies in Getting a diagnosis →